• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Aclaris Therapeutics (ACRS)

Common Shares
Sell: $4.05|Buy: $4.18|Change: 0.39 (10.40%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Address

640 Lee Road
Suite 200
Wayne
PA
USA
19087

Telephone

+1 484 3292140

Website

https://www.aclaristx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Aclaris Therapeutics Inc Fourth Quarter Earnings Results for 20262027-02-26T00:00:00
Aclaris Therapeutics Inc Annual Report for 20262027-02-26T00:00:00
Aclaris Therapeutics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Aclaris Therapeutics Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Aclaris Therapeutics Inc Annual General Meeting for 20262026-06-05T09:00:00
Aclaris Therapeutics Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
Aclaris Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-08T00:00:00

Previous key dates

NameKey Date
Leerink Global Healthcare Conference2026-03-10T13:40:00
Oppenheimer 36th Annual Healthcare Life Sciences Conference2026-02-26T08:40:00
Aclaris Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-26T00:00:00
Aclaris Therapeutics Inc Annual Report for 20252026-02-26T00:00:00
Guggenheim Emerging Outlook: Biotech Summit 20262026-02-12T14:30:00
Aclaris ATI-052 Interim Phase 1a Clinical Trial Results2026-01-06T08:00:00
Piper Sandler 37th Annual Healthcare Conference2025-12-02T11:00:00
Jefferies Global Healthcare Conference2025-11-17T09:00:00
Stifel 2025 Healthcare Conference2025-11-12T13:20:00
Guggenheim 2nd Annual Healthcare Conference2025-11-12T11:00:00
Aclaris Therapeutics Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
2025 R&D Day2025-10-14T08:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T09:00:00
Cantor Global Healthcare Conference2025-09-03T13:00:00
Aclaris Therapeutics Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
Aclaris Therapeutics ATI-2138 Phase 2a Results and ITK Franchise Update2025-07-29T17:00:00
Aclaris Therapeutics, Inc. H.C. Wainwright Inflammation & Immunology Virtual Conference 20252025-06-30T11:30:00
Goldman Sachs Global Healthcare Conference2025-06-11T13:20:00
Aclaris Therapeutics Inc Annual General Meeting for 20252025-06-05T09:00:00
Jefferies Global Healthcare Conference2025-06-04T10:30:00
HC Wainwright “HCW@Home” series2025-05-16T13:00:00
Aclaris Therapeutics Inc First Quarter Earnings Result for 20252025-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.